DUBLIN–(BUSINESS WIRE)–

Dublin – Research and Markets (http://www.researchandmarkets.com/research/3pfvk2/hnwi_asset_allocat)
has announced the addition of the “HNWI
Asset Allocation in France to 2015″ report to their offering.

This report is the result of Wealth Insight’s extensive research
covering the HNWI population and wealth management industry in France.
It provides detailed figures on the current and expected HNWI asset
allocations of French HNWIs to 2015.

Summary:

The report provides the latest asset allocations of French HNWIs. The
report also includes projections of the volume, wealth and asset
allocation of French HNWIs to 2015 and a comprehensive and robust
background of the local economy, including, uniquely, detailed analysis
of economic and political risks to HNWI wealth creation.

Scope:

The report features:

– Independent market sizing of French HNWIs

– Volume, wealth and allocation trends from 2007 to 2011

– Volume, wealth and allocation forecasts to 2015

– Insights into the drivers of HNWI wealth

Key Highlights:

– As of 2011, there are just over 555,000 HNWIs in France, with a
combined wealth of around US$2 trillion, accounting for roughly 16% of
France’s total wealth.

– In 2011, real estate is the largest asset class for HNWIs in France,
accounting for 24% of total HNWI assets, followed by fixed income,
business interests, equities, cash and alternatives.

– Fixed income and cash holdings were the best performing asset classes
over the review period, driven by flight to safety during and after the
global financial crisis. Against international norms, the share of HNWIs
assets held in real estate also increased substantially over the review
period, as the French real estate market outperformed global markets.

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Wealth Sector Fundamentals

4 Analysis of French HNWI Investments

5 Appendix

6 About WealthInsight

List of Tables ( 36 Total )

List of Figures ( 30 Total )

Companies Mentioned:

– AXA Bank Europe

– Barclays Wealth

– Credit Suisse

– Deutsche Bank

– Goldman Sachs

– HSBC Private Bank

– JP Morgan Private Banking

– Julius Baer

– Lazard Fr?res

– Pictet & Cie

– Quilvest

– Rothschild & Cie

– Sal. Oppenheim

– UBS Wealth

– Aforge Finance

– BNP Paribas

– Banque Transatlantique

– Bred Banque Priv?e

– CIC Banque

– Cr?dit Agricole

– Dexia Group

– Edmond de Rothschild

– EFG Banque Priv?e

– Gestion Priv?e Indosuez

– La Banque Postale

– Lazard Fr?res Banque

– LCL Banque Priv?e

– LCL S.A.

– Lombard Odier Darier Hentsch

– Martin Maurel

– Meeschaert Gestion Priv?e

– Natixis S.A.

– Neuflize OBC

– Oddo & Cie

– Postale Gestion Priv?e

– Priv?e Europ?enne

– SG Private Banking

– Actionnal

– Affectio Finance – Family Office

– Aforge Family Office

– Anthony & Cie

– Antium France Family Office

– Financi?re MJ

– Gosset Grainville Family Office

– Intuitae

– Janvier Participations

– La Fontaine Family Office

– Meeschaert Family Office

– Natixis SA – FO division

– Novances Family Office

– Patrimonial Management

– Pergam Finance

– Quilvest Family Office of Quilvest Banque Priv?e

– Riviera Family Office

– Societe Generale SA – FO division

– Unigestion – Family Office

For more information visit http://www.researchandmarkets.com/research/3pfvk2/hnwi_asset_allocat

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/5blttl/risk_management_f)
has announced the addition of the “Risk
Management: Fixed & Mobile Enterprise Adoption Trends”
report to their offering.

Business reliance on communications is high and ever increasing. The
integrity and reliability of fixed and mobile telecommunications
infrastructure, and the information carried across the infrastructure,
is essential to sustain business communications. To this end,
enterprises have a heightened sense of awareness about the vital nature
of telecommunications and are taking measures to identify, quantify and
mitigate risks that could prohibit the ability for the business to
communicate or compromise the information being communicated.

Risk management practices related to telecommunications management have
evolved as cloud computing and mobility have broadened the span of
accessibility to business information. In this regard, the emphasis of
risk management is primarily focused on information security and
technical integrity. Financial risk associated with service
unavailability is also a concern to be evaluated. Despite perceived
technical and financial threats, enterprises vary widely in the actions
they take to mitigate these risks. This research identifies adoption of
risk management practices across a variety of topics commonly cited as
potential threats to telecommunications, which could negatively impact
the business.

This research explores enterprise risk management trends and adoption of
risk management practices addressing:

– Contract and budget financial liability

– Infrastructure reliability

– Information and communications threats

– Telecom management supporting Disaster Recovery / Business Continuity

Anyone involved in fixed and mobile telecom management should read this
report in order to understand:

– How are other organizations mitigating technical, operational and
financial risk?

– Which industry verticals are most likely to be mitigating
organizational risk?

– What percentage of companies have a Disaster Recovery / Business
Continuity plan?

– What are the most prominent Disaster Recovery / Business Continuity
strategies being deployed today?

– Who ultimately owns the assessment and monitoring of specific risk
categories within an organization?

Along with answering these critical questions, this report provides the
following benchmarks:

– Risk Management Activities Performed

– Financial Risk Avoidance Activities

– Loss of Productivity Risk Avoidance Activities

– Information Security Risk Avoidance Activities

– Disaster Recovery / Business Continuity Plan Adoption – Overall

– Percentage of Organizations with a DR / BC Plan – By Company Size

– Specific DR / BC Strategies Deployed

– Mobile Device DR / BC Strategies

– Wireless Technology DR / BC Strategies

– Emergency Notification DR / BC Strategies

– Ownership of Assessing / Monitoring Risk

Study shows inconsistent adoption of telecommunications risk mitigation
practices across enterprises today

For more information visit http://www.researchandmarkets.com/research/5blttl/risk_management_f

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/lr88jn/post_menopausal_os)
has announced the addition of Global Markets Direct’s new report “Post
Menopausal Osteoporosis – Pipeline Review, H1 2012″ to their offering.

Global Markets Direct’s, ‘Post Menopausal Osteoporosis – Pipeline
Review, H1 2012′, provides an overview of the Post Menopausal
Osteoporosis therapeutic pipeline. This report provides information on
the therapeutic development for Post Menopausal Osteoporosis, complete
with latest updates, and special features on late-stage and discontinued
projects. It also reviews key players involved in the therapeutic
development for Post Menopausal Osteoporosis.

‘Post Menopausal Osteoporosis – Pipeline Review, H1 2012′ is built using
data and information sourced from Global Markets Direct’s proprietary
databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites
and industry-specific third party sources.

Scope

– A snapshot of the global therapeutic scenario for Post Menopausal
Osteoporosis.

– A review of the Post Menopausal Osteoporosis products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources.

– Coverage of products based on various stages of development ranging
from discovery till registration stages.

– A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.

– Coverage of the Post Menopausal Osteoporosis pipeline on the basis of
route of administration and molecule type.

– Profiles of late-stage pipeline products featuring sections on product
description, mechanism of action and research & development progress.

– Key discontinued pipeline projects.

– News and deals relating to the products.

Reasons to Buy

– Identify and understand important and diverse types of therapeutics
under development for Post Menopausal Osteoporosis.

– Identify emerging players with potentially strong product portfolio
and design effective counter-strategies to gain competitive advantage.

– Plan mergers and acquisitions effectively by identifying players with
the most promising pipeline.

– Devise corrective measures for pipeline projects by understanding Post
Menopausal Osteoporosis pipeline depth and focus of Post Menopausal
Osteoporosis therapeutics.

– Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.

– Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/lr88jn/post_menopausal_os

Source: Global Markets Direct

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/qx6j4n/fmcg_going_multich)
has announced the addition of the “FMCG
Going Multichannel 2012″ report to their offering.

We understand that Amazon is preparing for a full on push into online
grocery in the EU, after having laid the ground and quietly launched the
service two years ago, by leveraging their marketplace operation to its
fullest potential. The pureplay is undoubtedly pursuing the right
strategy, as online grocery is taking off all over Europe, with a
renewed effort by the leading retailers in 2010/11 to capture sales
migrating to the online channel.

This raises the question of how the FMCG industry should react to these
latest developments. After all the internet offers many possibilities to
reestablish a meaningful relationship with customers and regain control
over pricing, promotions and brand presentations – without having
retailers involved. We believe that the FMCG industry has to become
multichannel. Having an online presence also enables manufacturers to
engage in market research and launch effective loyalty solutions.

Launching a FMCG online presence now is especially vital, as many
retailers have started to use their private label propositions as a key
differentiator from the competition, rather than just a way of boosting
their margins. This means that repelling the private label push from
retailers will only become harder for the FMCG industry in future.

Key Topics Covered:

– FMCG strategic business model options to exploit the online
opportunity, with real live case examples.

– How FMCG are going multichannel, taking a leaf out of non food
consumer goods companies’ book to go fishing where the fish are

– Mobile shopping walls: the arrival of m-commerce, innovative
online/offline hybrid models.

– Consumers as drivers of change, demanding multichannel capabilities
and m-commerce linking off and online worlds.

– The emergence of click & collect as an incremental sales driver

– Online data revolution and how cutting edge companies exploit the
potential of the internet for future growth, leading to a structural
shift in retailing.

– Discusses whether current FMCG sites are market research projects or a
genuine sales drivers.

– Explains the significance of online FMCG marketplaces in terms of
sales contribution and sales growth driver, data warehouse, range
multiplier

– Sets out our view that marketplace operations are most suitable to
FMCG shoppers’ needs,

– In depth profiles of leading marketplace operators in the FMCG space,
Amazon, Alice.com and Rakuten, also discusses marketplace ventures by
Carrefour, Ocado and Wal-Mart

– Spells out the enormous advantages and benefits third party
marketplace operators (such as Amazon) enjoy from offering the solution
to sellers

– Provides an answer to the question whether the industry should run a
proprietary scheme and what to look out for when setting up a FMCG
marketplace with a variety of corporate partners

THIS REPORT WILL ALLOW YOU TO

– Benchmark your online strategy against leading, cutting edge operators

– Find out whether it makes sense to partner or to compete with Amazon,
Alice.com, Rakuten or any other marketplace operator

– Understand how to copy the best in class strategies of winning online
operators such as ecosystem development and loyalty driver creation

For more information visit http://www.researchandmarkets.com/research/qx6j4n/fmcg_going_multich

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/lffnp7/stem_cell_research)
has announced the addition of the “Stem
Cell Research Products: Opportunities, Tools & Technologies 2012
(Updated)” report to their offering.

Stem cells are primitive cells found in all multi-cellular organisms
that are characterized by self-renewal and the capacity to differentiate
into any mature cell type. Several broad categories of stem cells exist,
including embryonic stem cells, derived from blastocysts; fetal stem
cells, obtained from aborted fetuses; adult stem cells, found in adult
tissues; cord blood stem cells, isolated from umbilical tissue; dental
stem cells, derived from deciduous teeth; cancer stem cells, which give
rise to clonal populations of cells that form tumors or disperse in the
body; and animal stem cells, derived from non-human sources.

In a developing embryo, stem cells can differentiate into all of the
specialized embryonic tissues. In adult organisms, stem and progenitor
cells act as a repair system for the body, replenishing specialized
cells. Of interest to researchers is the potential for use of stem cells
in regenerative medicine to treat conditions ranging from diabetes, to
cardiovascular disease and neurological disorders. Additionally, the
ability to use stem cells to improve drug target validation and
toxicology screening is of intense interest to pharmaceutical companies.
Stem cells are also being studied for their ability to improve both the
understanding and treatment of birth disorders.

To facilitate research resulting from interest in these far-ranging
applications, a large and growing stem cells research products market
has emerged. Large companies selling stem cell research products include
Life Technologies, BD Biosciences, Thermo Fisher Scientific, and
Millipore, although dozens of other suppliers exist as well. Products
offered by these companies include: antibodies to stem cell antigens,
bead-based stem cell separation systems, stem cell protein purification
and analysis tools, tools for DNA and RNA-based characterization of stem
cells, stem cell culture and media reagents, stem cell specific growth
factors and cytokines, tools for stem cell gene regulation, a range of
stem cell services, tools for in vivo and in vitro stem cell tracking,
and stem cell lines.

This report explores current market conditions and provides guidance for
companies interested in developing strategically positioned stem cell
product lines.

Featured elements of this report include:

– What are novel stem cells research products that can be developed?

– What stem cells types are most frequently used by research scientists?

– Which species of stem cells do scientists prefer and what are the
factors driving this preference (access, pricing, funding, handling
advantages)?

– What are the most frequently used stem cell markers?

– What are the most common research applications, and how do they differ
by segment (academic, industrial, and government)?

– Who are the leading suppliers of stem cell products?

– What stem cell product categories are already available in the
marketplace?

– What are current grant, patent, and scientific publication rate trends?

– What are the major funding sources, trends, and dollar values, for
domestic and international researchers?

– What is the size of the stem cell research products marketplace and
how fast is it growing?

– What are communication strategies for accessing the marketplace?

– And much more…

In summary, the report provides detailed insight into the stem cells
research products marketplace and the needs of active stem cell
scientists.

Companies Mentioned:

– Cellartis AB

– Novocell

– Invitrogen

– Buck Institute

– BD Biosciences

For more information visit http://www.researchandmarkets.com/research/lffnp7/stem_cell_research

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/7q489w/global_brain_cance)
has announced the addition of the “Global
Brain Cancer Drug Pipeline Capsule – 2012″ report to their
offering.

Fore Pharma’s latest report Global Brain Cancer Drug Pipeline Capsule –
2012′ is an outline of all the key research and development (R&D)
activities of the global Brain Cancer drug market. It covers information
on key pipeline molecules in various stages of R&D including all the
phases of clinical trials, preclinical research, and drug discovery. The
report is up-to-date with full coverage of the licensing activities and
partnerships.

This report helps executives to keep a track of their competitors and
understand their pipeline molecules. The information presented in this
report can be used for identifying the partners, prioritizing,
evaluating opportunities, developing business development strategies,
and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and
mechanism of action across the different stages of R&D. It includes
registered / preregistered stage, phase 3 clinical trial, phase 2
clinical trial, phase 1 clinical trial, preclinical research, and drug
discovery. It also provides information on pipeline molecules developed
in leading geographies including the U.S., Canada, France, Germany,
U.K., Italy, and Spain by various stages of R&D. Licensing activities
and partnerships in the Brain Cancer drug market is thoroughly covered
by company and licensee with the deal summary.

Key Features of the Report:

– Brain Cancer: Overview

– Brain Cancer Drug Pipeline Overview

– Brain Cancer Phase 3 Clinical Trial Drug Pipeline Insights

– Brain Cancer Phase 2 Clinical Trial Drug Pipeline Insights

– Brain Cancer Phase 1 Clinical Trial Drug Pipeline Insights

– Brain Cancer Preclinical Research Drug Pipeline Insights

– Brain Cancer Drug Discovery Pipeline Insights

– Geographic Landscape of Brain Cancer R&D Activities

– Brain Cancer R&D Activities in North America

– Brain Cancer R&D Activities in Europe

– Licensing Activities / Partnerships in the Global Brain Cancer Drug
Market

For more information visit http://www.researchandmarkets.com/research/7q489w/global_brain_cance

DUBLIN–(BUSINESS WIRE)–

Dublin – Research and Markets (http://www.researchandmarkets.com/research/8p4b7q/global_gastric_can)
has announced the addition of the “Global
Gastric Cancer Drug Pipeline Capsule – 2012″ report to their
offering.

Fore Pharma’s latest report “Global Gastric Cancer Drug Pipeline Capsule
– 2012″ is an outline of all the key research and development (R&D)
activities of the global gastric cancer drug market. It covers
information on key pipeline molecules in various stages of R&D including
all the phases of clinical trials, preclinical research, and drug
discovery. The report is up-to-date with full coverage of the licensing
activities and partnerships.

This report helps executives to keep a track of their competitors and
understand their pipeline molecules. The information presented in this
report can be used for identifying the partners, prioritizing,
evaluating opportunities, developing business development strategies,
and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and
mechanism of action across the different stages of R&D. It includes
registered / preregistered stage, phase 3 clinical trial, phase 2
clinical trial, phase 1 clinical trial, preclinical research, and drug
discovery. It also provides information on pipeline molecules developed
in leading geographies including the U.S., Canada, France, Germany,
U.K., Italy, and Spain by various stages of R&D. Licensing activities
and partnerships in the gastric cancer drug market is thoroughly covered
by company and licensee with the deal summary.

Key Features of the Report:

– Gastric Cancer: Overview

– Gastric Cancer Drug Pipeline Overview

– Gastric Cancer Phase 3 Clinical Trial Drug Pipeline Insights

– Gastric Cancer Phase 2 Clinical Trial Drug Pipeline Insights

– Gastric Cancer Phase 1 Clinical Trial Drug Pipeline Insights

– Gastric Cancer Preclinical Research Drug Pipeline Insights

– Gastric Cancer Drug Discovery Pipeline Insights

– Geographic Landscape of Gastric Cancer R&D Activities

– Gastric Cancer R&D Activities in North America

– Gastric Cancer R&D Activities in Europe

– Licensing Activities / Partnerships in the Global Gastric Cancer Drug
Market

For more information visit http://www.researchandmarkets.com/research/8p4b7q/global_gastric_can

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/qts934/indian_chemical_in)
has announced the addition of the “Indian
Chemical Industry 2012″ report to their offering.

A key constituent of the Indian economy that accounts for about five
percent of the GDP, the Indian chemical industry has vital associations
with several other industries such as automotives, consumer durables,
food processing, iron and steel, textiles, paper, and engineering, among
others. It is the eighth largest sector in the world and the third
largest in Asia by volumes, after China and Japan. This report
encompasses an assessment of the chemicals industry in India, within the
context of the global industry, and the opportunities and challenges it
presents. The country’s chemical industry was estimated at USD 91
billion in 2011 and the authors believe that it has the potential to
reach USD 134 billion by 2015 growing at a CAGR of 10 percent. The
growth is expected to be driven by rising demand in end-use segments and
expanding exports fueled by increasing export competitiveness. The
dynamics that propel the industry, namely opportunities, competition,
infrastructure investment and regulatory policies are also studied in
the report.

The industry is a multi-product and multi-faceted one that comprises
basic chemicals, pharmaceuticals, petrochemicals, specialty chemicals,
agrochemicals and biotechnology and their sub segments. Within the sub
segments, the petrochemicals industry is growing the fastest, with a
rate of around 15 percent annually.

In India, the per-capita consumption of most of the finished products
under the chemicals sector is far below the world average, which
demonstrates the industry’s enormous potential for growth. The
government of India plans to invest USD 34 billion in three approved
Petroleum, Chemicals and Petrochemicals Investment Regions (PCPIRs); it
also plans to establish port-based chemical parks in special economic
zones (SEZs) in the next five years.

India has the potential to become a global chemical manufacturing hub if
the government and domestic players rise up to the challenge. It is
projected that USD 350 billion of the projected USD 1 trillion global
specialty chemical industry could move to Asia by 2020. In wake of this,
immense growth opportunities coupled with intense competition are acting
as major drivers behind the dynamic growth in certain segments.

SCOPE OF THE REPORT

-Overview of Indian Chemical Industry

-Detailed Analysis of the Segments

-Outlook of the Industry

KEY FEATURES DISCUSSED

-Indian & Global Chemical Market size and Outlook

-Production and Installed Capacity of Major Chemicals and Petrochemicals

-Chemical Market Analysis and Forecast

-Growth Drivers of the Industry

-Regional Concentration of the Industry

-Key Investments in the Chemicals Sector

-Comparative Cost Structure

-SWOT Analysis

-Issues and Challenges and Regulatory Framework

-Profiles of Key Players

WHY ONE SHOULD BUY THE REPORT

-Comprehensive Outlook of the Industry

-Segment-wise Analysis and Trends

-Current Status and Prospect

-Opportunities in Various Segments of the Industry

BENEFICIARIES OF THE REPORT

-Indian and Global Chemical Companies

-Government Entities and Policy Makers

-Agrochemical and Biotechnology Companies

-Educational Institutes and Research Centers

-Business Research, KPO & Consulting Companies

-Commercial Banks and Financial Institutions

-Individuals/Investors

Key Topics Covered:

1. Executive Summary

2. Overview

3. Indian Chemical Industry

4. SWOT Analysis

5. Regulatory Framework

6. Issues and Challenges

7. Opportunities

8. Cost Structure

9. Investments

10. Major Players

11. Outlook

Companies Mentioned

– TCL

– RIL

– UPL

– GACL

– Pidilite

– IGL

For more information visit http://www.researchandmarkets.com/research/qts934/indian_chemical_in